Clinical Benefits of <i>Boswellia Serrata</i> (BOSMAX®) in Early Knee Osteoarthritis: A Randomized, Placebo-Controlled, Double-Blind Study

Osteoarthritis (OA) is a major cause of pain and reduced mobility in older adults, with few effective treatments currently available. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of <i>Boswellia serrata</i> extract (BOSMAX®), a botanical anti-inflammatory agent, in participants with non/mild OA. A total of 150 adults aged 40-75 were randomized to receive either BOSMAX® or a placebo daily for 90 days. Primary outcome measures included WOMAC scores, visual analog scale (VAS) for pain, and Lequesne Functional Index; secondary endpoints were SF-36 scores, tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP). Significant improvements were observed in the BOSMAX® group compared with the placebo. The mean total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores decreased significantly at days 30 (-6.28), 60 (-15.24), and 90 (-24.55; <i>P</i> < .05). WOMAC sub-scores (pain, stiffness, and function) and VAS pain scores also showed significant reductions at days 60 and 90. Lequesne Index scores improved progressively (-1.37, -2.93, and -4.53 at days 30, 60, and 90, respectively; <i>P</i> < .05). TNF-α and hs-CRP levels decreased significantly (-104.75 ng/L and -5.67 ng/mL, respectively; <i>P</i> < .05) at day 90. However, no significant changes were observed in SF-36 scores. Both treatments exhibited good tolerability, with only one mild and unrelated adverse event reported. Vital signs, physical exams, and laboratory parameters remained clinically unchanged. BOSMAX® significantly improved knee-joint symptoms and inflammatory markers over 90 days in individuals with non/mild OA, supporting its potential as a safe therapeutic option.